Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Jun 4, 2015 (11 years ago)

Lutera (0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol tablets USP)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Labeling: Incorrect or Missing Package Insert; Product is being recalled because the birth control packs were distributed with out-dated package inserts.

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Lutera (0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol tablets USP), 28 day Regimen, 6 Tablet Dispensers per box, 28 Tablets Each, Rx Only, Manufactured for: Watson Pharm, Inc., a subsidiary of Watson Pharmaceutical, Inc., Corona, CA 92880, Manufactured by: Patheon, Inc., Mississauga, Ontario L9N7K9 Canada, NDC 52544-0949-28

Affected NDC 52544-0949-28

Compare with the code on your package — it is the most precise check available.

Drug: Estradiol

Recalling firm
Actavis Inc
NDC code
52544-0949-28
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1148-2015 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Estradiol recalls

See all
Class II · Moderate risk

Alyacen 7/7/7

Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities.

Ongoing Impurity / degradation Glenmark Pharmaceuticals Inc., USA NDC 68462-556-29 D-0588-2026
Class II · Moderate risk

Estradiol Gel

Defective Container; packets were found to be either empty or partially full.

Ongoing Packaging defect ANI Pharmaceuticals, Inc. NDC 70954-531-20 D-0543-2026
Class II · Moderate risk

Estradiol

Presence of Foreign substance - potential presence of metal particulate matter

Ongoing Particulate / foreign matter F.H. INVESTMENTS, Inc. (dba Asteria Health) D-0315-2026
Class II · Moderate risk

Estradiol

Presence of Foreign substance - potential presence of metal particulate matter

Ongoing Particulate / foreign matter F.H. INVESTMENTS, Inc. (dba Asteria Health) D-0314-2026
Class II · Moderate risk

Estradiol

Presence of Foreign substance - potential presence of metal particulate matter

Ongoing Particulate / foreign matter F.H. INVESTMENTS, Inc. (dba Asteria Health) D-0313-2026

Other recalls by Actavis Inc

All 2015 recalls
Class III · Low risk

Levofloxacin Ophthalmic Solution

Failed Impurities/ Degradation Specifications: OOS for related compound (levofloxacin n-oxide) at the 18 month stability time point.

Terminated Impurity / degradation Actavis Inc NDC 50383-283-05 D-0514-2017
Class II · Moderate risk

Glipizide extended-release tablets

Failed Dissolution Specifications. Above out of specification for dissolution rate observed at the 10 hour testing point.

Terminated Dissolution failure Actavis Inc NDC 0591-0900-30 D-0476-2017
Class III · Low risk

Hydrocortisone and acetic acid otic solution

Failed Impurities/Degradation Specifications: Out of specification (OOS) results for related compound G were obtained at 12-month (at expiry) stability time-point for room temperature sample(s).

Terminated Impurity / degradation Actavis Inc NDC 45963-412-61 D-1472-2016